Peer-reviewed veterinary case report
High-dose carvedilol for cats with early obstructive heart disease
By Satomi, Shuji et al.·Published in Journal of feline medicine and surgery·2026·Department of Veterinary Science, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of high-dose carvedilol treatment for cats with stage B1 obstructive hypertrophic cardiomyopathy.
- Species:
- cat
Plain-English summary
A group of cats with obstructive hypertrophic cardiomyopathy (oHCM), a heart condition that can cause breathing problems and lethargy, were treated with a higher dose of carvedilol after a standard dose didn't help enough. The higher dose significantly reduced the obstruction in their hearts and improved heart function without causing any side effects. Most of the cats showed marked improvement in their heart measurements and overall health after the treatment. This suggests that high-dose carvedilol can be an effective option for managing this condition in cats.
People also search for: cat heart disease treatment · carvedilol for cats · obstructive hypertrophic cardiomyopathy in cats
Abstract
ObjectivesThe aim of the study was to investigate the effects of high-dose (HD) carvedilol treatment in client-owned cats with stage B1 obstructive hypertrophic cardiomyopathy (oHCM) where a standard dose (SD) had failed to adequately alleviate left ventricular outflow tract (LVOT) obstruction.MethodsA prospective, interventional study was conducted in which cats underwent echocardiography, including evaluation of myocardial strain using speckle-tracking echocardiography. Myocardial injury was quantified using a cardiac troponin I (cTnI) assay. Echocardiographic variables and the cTnI level were compared before treatment and after SD and HD carvedilol treatment.ResultsLVOT velocity (LVOTV) decreased after SD compared with before treatment in all cats, but remained above 2.5 m/s after SD (before treatment 4.9 m/s [interquartile range [IQR] 4.3-5.0]; SD 4.3 m/s [IQR 3.9-4.7]), whereas HD decreased LVOTV to below 2.5 m/s in 10/11 cats (1.6 m/s [IQR 1.5-2.0]). Longitudinal strain was improved after SD and HD compared with before treatment (endocardial layer: before treatment 12.1% [IQR 9.6-15.8]; SD 20.0% [IQR 15.9-21.7]; HD 18.9% [IQR 12.9-22.8]; = 0.003 and = 0.006, respectively; epicardial layer: before treatment 9.4% [IQR 7.0-10.7]; SD 11.6% [IQR 10.0-12.7]; HD 12.5% [IQR 10.0-13.3]; = 0.013 and = 0.001, respectively). Circumferential strain demonstrated no changes. The cTnI level decreased after SD and HD compared with before treatment, and after HD compared with SD (before treatment 0.334 ng/ml [IQR 0.117-0.931]; SD 0.192 ng/ml [IQR 0.111-0.377]; HD 0.018 ng/ml [IQR 0.009-0.161]; = 0.043, = 0.043 and = 0.043, respectively). No cats experienced adverse effects such as bradycardia or hypotension.Conclusions and relevanceHD improved LVOTV, myocardial function and cTnI level without adverse effects in cats with stage B1 oHCM.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41792123/